According to nominal p-values for interaction, we found better preservation of eGFR over time with dapagliflozin vs comparators in patients with longer diabetes duration, below-median baseline eGFR, CKD, UACR>30 mg/g, microangiopathy, or using insulin. Here, INS is linked to chronic kidney disease.